One-Time Intravitreal Injection of KVD001, a Plasma Kallikrein Inhibitor, in Patients with Central Involved Diabetic Macular Edema and Reduced Vision: An Open-Label Phase 1B Study
Sun JK, Maturi RK, Boyer DS, Wells JA, Gonzalez VH, Tansley R, Hernandez H, Maetzel A, Feener EP, Aiello LP.


Rapid and nearly complete suppression of plasma kallikrein activity with the oral inhibitor KVD900: results of a phase 1 study evaluating KVD900's potential as a treatment for acute attacks of HAE
Maetzel A, Smith MD, Morten RM, Hampton SL, De Donatis GM, Murugesan NI, Rushbrooke LJ, Li L, Duckworth EJ, Feener EP, Yea C.

EAACI 2019

KVD900, a new oral on-demand treatment of hereditary angioedema attacks achieves complete plasma kallikrein suppression; safety, tolerability, pharmacokinetic and pharmacodynamic results from a phase 1 first-in-human study.
Maetzel A, Smith M, Duckworth EJ, Hampton SL, De Donatis GM, Murugesan N, Rushbrooke L, Li L, Francombe D, Feener EP and Yea C.


High plasma exposures of KVD900 achieved in First in Human study markedly inhibit plasma prekallikrein activation; early blockade of plasma kallikrein (PKa) may halt attacks in Hereditary Angioedema (HAE) by reducing contact system activation.
Duckworth EJ, Hampton SL, Li L, Murugesan N, Rushbrooke L, Smith M, Morten R, Maetzel A, Yea C, and Feener EP.


Novel oral plasma kallikrein (PKa) inhibitors KV998052 and KV998054 ameliorate VEGF-induced retinal thickening in a murine model of retinal edema.
Murugesan N, Clermont AC, Pethen SJ, Li L, Duckworth EJ, Hampton SL, and Feener EP.

ARVO 2019

KVD900 as a Single Dose, Rapid, Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema Attacks: Pharmacokinetic and Pharmacodynamic results from a Phase 1 Single Ascending Dose Study.
Hampton SL, De Donatis GM, Murugesan N, Rushbrooke LJ, Li L, Duckworth E, Smith MD, Morten RM, Maetzel A, Yea CM and Feener EP.
AAAAI 2019

Efficacy of plasma kallikrein inhibitors in plasma is dependent on the rate of formation of the enzyme-inhibitor complex.
De Donatis GM, Murugesan N, Duckworth E, Robson PA, Li L, Rushbrooke LJ, Feener EP and Hampton SL.
KININ 2018

KVD900 protects high molecular weight kininogen (HK) from ex vivo plasma kallikrein-mediated cleavage in plasma from patients with hereditary angioedema (HAE): Results from a semi-automated capillary-based immunoassay.
Feener EP, Murugesan N, Robson PA, Li L, Rushbrooke LJ, Thoonen R, De Donatis GM, Riedl M, Zuraw B, and Hampton SL.
EAACI 2018

A novel oral plasma kallikrein (PKal) inhibitor KV123833 blocks VEGF-mediated retinal vascular hyperpermeability in a murine model of retinal edema (#3464).
Murugesan N, Clermont AC, Rushbrooke LJ, Robson PA, Thoonen R, Pethen SJ, Hampton SL, and Feener EP. 
ARVO 2018

Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke.
Simao F, Ustunkaya T, Clermont AC, and Feener EP. 
Blood. 2017.

Plasma Kallikrein Mediates Vascular Endothelial Growth Factor-Induced Retinal Dysfunction and Thickening.
Clermont A, Murugesan N, Zhou Q, Kita T, Robson PA, Rushbrooke LJ, Evans DM, Aiello LP, and Feener EP.
Invest Ophthalmol Vis Sci. 2016; 57:2390-9.

Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema.
Kita T, Clermont AC, Murugesan N, Zhou Q, Fujisawa K, Ishibashi T, Aiello LP, Feener EP.
Diabetes. 2015; 64:3588-99.

Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein.
Liu J, Clermont AC, Gao BB, Feener EP.
Invest Ophthalmol Vis Sci. 2013;54:1086-1094.

Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats.
Clermont A, Chilcote TJ, Kita T, Liu J, Riva P, Sinha S and Feener EP.
Diabetes. 2011;60(5):1590-8.

Hyperglycemia induced cerebral hematoma expansion is mediated by plasma kallikrein.
Liu J, Gao B-B, Clermont AC, Blair P, Chilcote TJ, Sinha S, Flaumenhaft R and Feener EP.
Nature Medicine. 2011;17:206-10.

Plasma kallikrein and diabetic macular edema.
Feener EP.
Curr. Diab. Rep. 2010 Aug; 10(4):270-5.

Plasma kallikrein mediates angiotensin AT1 receptor stimulated retinal vascular permeability.
Phipps JA, Clermont AC, Sinha S, Chilcote TJ, Bursell S-E, and Feener EP.
Hypertension 2009; 53:175-81.

The kallikrein-kinin system in diabetic retinopathy: Lessons for the kidney.
Phipps JA and Feener EP.
Kidney Int., 2008;73(10):1114-9.

Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation.
Gao BB, Clermont A, Rook S, Fonda SJ, Srinivasan VJ, Wojtkowski M, Fujimoto JG, Avery RL, Arrigg PG, Bursell SE, Aiello LP and Feener EP.
Nature Medicine. 2007;13:181-8.